Myotonic Dystrophy Market Expected to Grow Rapidly During the Forecast Period (2026-2036) as Pipeline Therapies Address Unmet Medical Needs | DelveInsight

The 7MM myotonic dystrophy treatment market was valued at $236 million in 2025, with approximately 110,000 diagnosed patients, and is forecast to expand through 2036 as genetic testing, diagnosis, and RNA-targeted therapies advance. The pipeline includes candidates from AMO Pharma, Dyne, PepGen, Vertex and Sarepta, while AMO-02 has agreed registrational-study designs with U.S., U.K. and Canadian regulators. Offsetting the positive pipeline outlook, Novartis/Avidity's delpacibart etedesiran failed its Phase III primary endpoint in DM1, underscoring substantial clinical-development risk in a market with no approved disease-modifying or curative therapy.

Analysis

The relevant investable read-through is not market-size growth but a reset in DM1 modality risk: failure of a late-stage muscle-targeted RNA program materially raises the evidentiary bar for every platform claiming target knockdown can translate into durable functional benefit. NVS can absorb the direct setback, but DYN and PEPG now carry greater binary sensitivity to clinical endpoints that demonstrate patient function, not biomarker movement; their multiples are likely to trade more tightly around upcoming data releases over the next 1-3 months.

DYN is the clearest near-term catalyst vehicle: one-year data can distinguish whether sustained delivery produces a widening functional separation versus merely durable molecular/pharmacodynamic effects. Positive durability would support a relative rerating versus PEPG, whose program remains earlier and must still establish both delivery and clinical relevance. Conversely, a weak functional update would imply that the sector's apparent technical de-risking has been overstated and could produce broad 20-35% downside across DM1-focused development-stage names.

The commercial prize should be discounted more heavily than typical rare-disease models imply. A small diagnosed population, heterogeneous progression, multisystem disease, and payer demand for meaningful functional outcomes constrain premium pricing and penetration; expanding diagnosis is not equivalent to immediately monetizable treated prevalence. The contrarian opportunity is that NVS's negative result may be over-extrapolated across modalities: a failure can reflect dose, tissue distribution, endpoint selection, or trial design rather than invalidating RNA intervention, but only a replicated functional signal can resolve this.

Maintain skepticism toward broad pipeline lists as trade signals. VRTX and SRPT have DM1 optionality but the indication is immaterial to consolidated valuation; any sympathy movement in those large caps should be viewed as an opportunity to avoid assigning DM1 value until program-specific human data establish efficacy.

Key Decisions for Investors

• Event-driven long DYN / short PEPG pair into the late-September/early-October one-year DYN data window; size modestly given binary risk. Thesis requires durable functional benefit alongside acceptable safety. Target 15-25% relative upside if data validate clinical translation; exit if functional endpoints fail to improve or safety limits chronic dosing.
• Do not add NVS on the DM1 setback alone: the direct financial impact is immaterial, while the signal is strategically important only if management reduces broader RNA-therapeutics investment or guidance. Monitor the next earnings call for pipeline-prioritization language rather than treating the headline as a fundamental NVS short catalyst.
• Use any broad post-data rally in SRPT or VRTX attributable to DM1 pipeline enthusiasm to trim/short tactically against biotech exposure; DM1 is too small to alter their earnings power within 6-18 months. Cover if either company discloses compelling human functional data or a partnership that shifts development funding materially.
• Set an alert for DYN's presentation: prioritize changes in objective functional measures, durability through one year, discontinuations, and dose-response—not target knockdown. A clean biomarker-only update is a no-trade outcome and should not justify a multiple expansion.